Advertisement
Canada markets closed

  • S&P/TSX

    22,308.93
    -66.90 (-0.30%)
     

  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     

  • DOW

    39,512.84
    +125.08 (+0.32%)
     

  • CAD/USD

    0.7317
    +0.0006 (+0.08%)
     

  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     

  • Bitcoin CAD

    83,240.62
    -2,787.34 (-3.24%)
     

  • CMC Crypto 200

    1,261.13
    -96.88 (-7.13%)
     

  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     

  • RUSSELL 2000

    2,059.78
    -13.85 (-0.67%)
     

  • 10-Yr Bond

    4.5040
    +0.0550 (+1.24%)
     

  • NASDAQ

    16,340.87
    -5.40 (-0.03%)
     

  • VOLATILITY

    12.55
    -0.14 (-1.10%)
     

  • FTSE

    8,433.76
    +52.41 (+0.63%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • CAD/EUR

    0.6789
    +0.0011 (+0.16%)
     
MARKETS LIVE BLOG:

STOCKS CLIMB AS DOW POSTS 8TH STRAIGHT WIN

Fed's Michelle Bowman echoes higher-for-longer mantra for interest rates

Blackstone to acquire BioMed in deal valued at $8B

CNBC
Updated
BioMed Realty Trust on Thursday announced that it agreed to be acquired by Blackstone in an all-cash deal valued at $8 billion.

Healthcare REIT BioMed Realty Trust (BMR) said it had agreed to be bought by Blackstone (BX) in a deal valued at $8 billion.

The all-cash offer of $23.75 per share represents a premium of 10 percent to BioMed's close of $21.59 on Wednesday.

BioMed, which owns office buildings catering to pharma and biotech companies, has interests in properties comprising about 18.8 million rentable square feet.

The offer, which has been approved by BioMed's board, represents a premium of 24 percent to BioMed's closing price on Sept. 22, when Bloomberg first reported of Blackstone's interest.

The deal is expected to close in the first quarter of 2016.

Morgan Stanley (MS) is lead financial adviser to BioMed Realty. Citigroup Global Markets (C), J.P. Morgan Securities (JPM) and Bank of America/Merrill Lynch (BAC) are advising Blackstone.